Physician profile
Sandy Botros
NPI 1952785487
$925.76
in general payments reported to CMS, 2019-2025
19 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.69 · 2023: $84.14 · 2024: $420 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $141.14 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $116.36 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $91.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $85.64 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $68.05 | 2023-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $65.62 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.12 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $43.02 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $38.48 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $33.00 | 2023-2024 | Heplisav-B |
| Amgen INC. | $30.82 | 2024-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $24.58 | 2024 | Auvelity |
| Pfizer INC. | $23.55 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.23 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.06 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $15.71 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $13.72 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.